1
|
Bougas N, Allodji RS, Fayech C, Haddy N, Mansouri I, Journy N, Demoor C, Allard J, Thebault E, Surun A, Pacquement H, Pluchart C, Bondiau PY, Berchery D, Laprie A, Boussac M, Jackson A, Souchard V, Vu-Bezin G, Dufour C, Valteau-Couanet D, de Vathaire F, Fresneau B, Dumas A. Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up? Br J Cancer 2023; 129:1298-1305. [PMID: 37604931 PMCID: PMC10575933 DOI: 10.1038/s41416-023-02400-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Revised: 07/13/2023] [Accepted: 08/10/2023] [Indexed: 08/23/2023] Open
Abstract
BACKGROUND We aimed to study adherence to cardiac screening in long-term childhood cancer survivors (CCS) at high risk of cardiomyopathy. METHODS This study involved 976 5-year CCS at high risk for cardiomyopathy from the French Childhood Cancer Survivor Study. Determinants of adherence to recommended surveillance were studied using multivariable logistic regression models. Association of attendance to a long-term follow-up (LTFU) visit with completion of an echocardiogram was estimated using a Cox regression model. RESULTS Among participants, 32% had an echocardiogram within the 5 previous years. Males (adjusted RR [aRR] 0.71, 95% CI 0.58-0.86), survivors aged 36-49 (aRR 0.79, 95% CI 0.64-0.98), Neuroblastoma (aRR 0.53, 95% CI 0.30-0.91) and CNS tumour survivors (aRR 0.43, 95% CI 0.21-0.89) were less likely to adhere to recommended surveillance. Attendance to an LTFU visit was associated with completion of an echocardiogram in patients who were not previously adherent to recommendations (HR 8.20, 95% CI 5.64-11.93). CONCLUSIONS The majority of long-term survivors at high risk of cardiomyopathy did not adhere to the recommended surveillance. Attendance to an LTFU visit greatly enhanced the completion of echocardiograms, but further interventions need to be developed to reach more survivors.
Collapse
Grants
- Institut National Du Cancer (French National Cancer Institute)
- This study was supported by the INCa/ARC foundation (CHART project). The FCCSS cohort is supported and funded by the French Society of Cancer in Children and adolescents (SFCE), the Gustave Roussy Foundation (Pediatric Program “Guérir le Cancer de l’Enfant”), the Foundation ARC (POPHarC program) and The French National Research Agency (ANR, HOPE-EPI project), the ‘Ligue Nationale Contre le Cancer’, and the ‘Programme Hospitalier de Recherche Clinique’.
- This work was supported by the INCa/ARC foundation (CHART project). The FCCSS cohort is supported and funded by the French Society of Cancer in Children and adolescents (SFCE), the Gustave Roussy Foundation (Paediatric Program “Guérir le Cancer de l’Enfant”), the Foundation ARC (POPHarC program) and The French National Research Agency (ANR, HOPE-EPI project), the ‘Ligue Nationale Contre le Cancer’, and the ‘Programme Hospitalier de Recherche Clinique’.
Collapse
Affiliation(s)
- Nicolas Bougas
- Université Paris Cité, Inserm, ECEVE UMR 1123, F-75010, Paris, France.
| | - Rodrigue S Allodji
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Chiraz Fayech
- Gustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France
| | - Nadia Haddy
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Imene Mansouri
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Neige Journy
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Charlotte Demoor
- SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France
| | - Julie Allard
- Gustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France
| | - Eric Thebault
- Gustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France
- Department of Tumor Pediatrics, Centre Oscar Lambret, 59000, Lille, France
| | - Aurore Surun
- SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France
| | - Hélène Pacquement
- SIREDO Oncology Center (Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer), Institut Curie, PSL University, Paris, France
| | - Claire Pluchart
- Institut de Cancérologie Jean Godinot, F-51100, Reims, France
| | | | - Delphine Berchery
- Department of Radiation Oncology, University Institute of Cancer Toulouse-Oncopôle, Toulouse, France
| | - Anne Laprie
- Department of Radiation Oncology, University Institute of Cancer Toulouse-Oncopôle, Toulouse, France
| | - Marjorie Boussac
- Santé publique France, the National Public Health Agency, Saint-Maurice, France
- French National Health Insurance (Cnam), Paris, France
| | - Angela Jackson
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Vincent Souchard
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Giao Vu-Bezin
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Christelle Dufour
- Gustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France
| | - Dominique Valteau-Couanet
- Gustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France
| | - Florent de Vathaire
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Department of Clinical Research, F-94805, Villejuif, France
| | - Brice Fresneau
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
- Gustave Roussy, Université Paris-Saclay, Department of Children and Adolescents Oncology, Villejuif, F-94805, France
| | - Agnès Dumas
- Université Paris Cité, Inserm, ECEVE UMR 1123, F-75010, Paris, France
- Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, F-94805, France
| |
Collapse
|